Liquidia Corporation (NASDAQ:LQDA) Stock Has Consensus Target Price of $75.23

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) has received an average rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $75.23.

LQDA has been the subject of several research reports. Bank of America set a $54.00 price objective on Liquidia and gave the company a “neutral” rating in a report on Wednesday, November 11th. Royal Bank Of Canada set a $65.00 target price on Liquidia in a research note on Thursday, October 15th. Wells Fargo & Company upped their price target on Liquidia from $33.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 11th. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Finally, Wedbush set a $58.00 price target on Liquidia in a research note on Friday, October 2nd.

View Our Latest Analysis on Liquidia

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 9,218 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $262,528.64. Following the sale, the insider directly owned 126,368 shares of the company’s stock, valued at $3,598,960.64. This represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Dana Boyle sold 1,581 shares of the company’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $43.19, for a total transaction of $68,283.39. Following the sale, the chief accounting officer directly owned 164,028 shares in the company, valued at approximately $7,084,369.32. This trade represents a 0.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 537,045 shares of company stock worth $23,476,727 in the last ninety days. 25.60% of the stock is owned by corporate insiders.

Institutional Trading of Liquidia

A number of institutional investors have recently modified their holdings of LQDA. The Manufacturers Life Insurance Company grew its position in shares of Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after purchasing an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Liquidia during the 2nd quarter worth about $29,694,000. Seven Fleet Capital Management LP lifted its holdings in Liquidia by 25.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Liquidia during the 2nd quarter worth about $1,236,000. Finally, Bank of America Corp DE lifted its holdings in Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Price Performance

LQDA opened at $56.37 on Tuesday. The firm has a market cap of $5.08 billion, a P/E ratio of -45.83, a PEG ratio of 1.39 and a beta of 0.40. The firm has a 50-day moving average of $48.72 and a 200 day moving average of $54.82. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 1.02. Liquidia has a fifty-two week low of $22.31 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($2.64) EPS for the quarter, missing the consensus estimate of $0.96 by ($3.60). The company had revenue of $225.30 million during the quarter, compared to the consensus estimate of $214.18 million. Liquidia had a positive return on equity of 264.65% and a negative net margin of 15.15%. The business’s revenue was up 314.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) EPS. On average, research analysts expect that Liquidia will post -0.25 EPS for the current year.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.

Recommended Stories

Analyst Recommendations for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.